These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 12362101

  • 1. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM.
    Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
    [Abstract] [Full Text] [Related]

  • 2. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K, Recker DP, Verburg KM.
    Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S.
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.
    JAMA; 2000 Sep 13; 284(10):1247-55. PubMed ID: 10979111
    [Abstract] [Full Text] [Related]

  • 5. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 13; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 6. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):527-38. PubMed ID: 15339324
    [Abstract] [Full Text] [Related]

  • 7. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA.
    Am J Gastroenterol; 2005 May 01; 100(5):1043-50. PubMed ID: 15842577
    [Abstract] [Full Text] [Related]

  • 8. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.
    JAMA; 1999 Nov 24; 282(20):1929-33. PubMed ID: 10580458
    [Abstract] [Full Text] [Related]

  • 9. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
    White WB, Strand V, Roberts R, Whelton A.
    Am J Ther; 2004 Nov 24; 11(4):244-50. PubMed ID: 15266215
    [Abstract] [Full Text] [Related]

  • 10. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
    Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP.
    J Fam Pract; 2002 Jun 24; 51(6):530-7. PubMed ID: 12100776
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
    Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J.
    Gastroenterology; 1999 Oct 24; 117(4):776-83. PubMed ID: 10500058
    [Abstract] [Full Text] [Related]

  • 12. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr 24; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
    Makarowski W, Zhao WW, Bevirt T, Recker DP.
    Osteoarthritis Cartilage; 2002 Apr 24; 10(4):290-6. PubMed ID: 11950252
    [Abstract] [Full Text] [Related]

  • 14. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE.
    Aliment Pharmacol Ther; 1999 Jun 24; 13(6):761-7. PubMed ID: 10383505
    [Abstract] [Full Text] [Related]

  • 15. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
    Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, James C, Bowen B, Rashid F.
    Aliment Pharmacol Ther; 2003 Jan 24; 17(2):201-10. PubMed ID: 12534404
    [Abstract] [Full Text] [Related]

  • 16. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG.
    J Rheumatol; 1998 Aug 24; 25(8):1602-11. PubMed ID: 9712107
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM, Goldstein JL, Hanna DB, Rublee DA.
    Aliment Pharmacol Ther; 2005 Mar 01; 21(5):591-8. PubMed ID: 15740543
    [Abstract] [Full Text] [Related]

  • 18. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, Feng H, Parsons B.
    Int J Rheum Dis; 2010 May 01; 13(2):151-7. PubMed ID: 20536600
    [Abstract] [Full Text] [Related]

  • 19. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
    Harris SI, Kuss M, Hubbard RC, Goldstein JL.
    Clin Ther; 2001 Sep 01; 23(9):1422-8. PubMed ID: 11589257
    [Abstract] [Full Text] [Related]

  • 20. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
    Ashcroft DM, Chapman SR, Clark WK, Millson DS.
    Ann Pharmacother; 2001 Sep 01; 35(7-8):829-34. PubMed ID: 11485128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.